Hakan Ergün
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hakan Ergün has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
- Sinem Ezgi Gulmez
Department of Medical Pharmacology Koç University School of Medicine Istanbul Turkiye
6 shared publications - Burak Kaya
Department of Plastic, Reconstructive and Aesthetic Surgery, Ankara University Faculty of Medicine, Ankara, Türkiye
3 shared publications A. Uluç
Ankara University Faculty of Medicine
2 shared publicationsCüneyt Köksoy
2 shared publications- Ediz Demirpençe
Department of Biochemistry, Faculty of Medicine, Hacettepe University
2 shared publications - Emine Demirel-Yilmaz
Department of Medical Pharmacology, Faculty of Medicine, Ankara University, Sihhiye, Ankara, Turkey
2 shared publications
Latest Publications
- 10 November 2024
- Published by Elsevier in Tissue and Cell
- Vol. 91, 102607
Evaluation of resveratrol's protective effect on hydrocortisone-induced growth inhibition in the peripubertal rat epiphyseal plate
- 10 November 2024
- Published by Elsevier in Tissue and Cell
- Vol. 91, 102607
Evaluation of resveratrol's protective effect on hydrocortisone-induced growth inhibition in the peripubertal rat epiphyseal plate
- Open Access
- 20 February 2024
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 19 (1) , 1-10
Phenylketonuria from the perspectives of patients in Türkiye
Background: The present study aimed to determine the problems, unmet needs and expectations of phenylketonuria (PKU) patients in Türkiye regarding follow-up and treatment in order to provide data for future planning and implementations on PKU. Methods: The study included patients diagnosed with PKU and/or their parents. They were informed about the study via phone calls and their verbal consents were obtained. Questions in the data collection forms, which were established separately for pediatric, adolescent, and adult age groups, were applied during the interviews and the answers were recorded. Results: Among 182 classical PKU patients, 66 (36.3%) were in the pediatric group (0–12 years old), 44 (24.2%) were in the adolescent group (13–19 years old), and 72 (39.5%) were in the adult group (≥ 20 years old). In all patient groups, phenylalanine-restricted diet and medical nutrition products were the main options for treatment. The median of the last measured blood phenylalanine concentration (patient-reported) was 290 µmol/L, 425 µmol/L, and 750 µmol/L in the pediatric, adolescent, and adult groups, respectively. The frequency of blood testing for serum phenylalanine level according to the age groups was appropriate in nearly half of the patients. While the majority of the patients have been visiting the metabolism center they have been diagnosed with PKU for control, considerable proportion of the patients would like to change the center or the doctor they visit for control if they could. It was determined that nearly half of the patients had trouble in accessing the metabolism center. Treatment options’ being limited and expensive were the major problems. The main requests of the patients and patient relatives included easier access to the metabolism centers and more options for treatment and diet. Conclusions: Access to the services should be easier to improve the patients’ follow-up and treatment. There is need for low-cost, easily applicable, and accessible nutrition products and effective novel pharmacological agents. Focusing on these issues in health policies by providing pedagogic/psychological support, establishing support programs also comprising the families, and increasing the awareness activities were the key outcomes.
- 20 February 2024
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 19 (1) , 1-10
Open AccessPhenylketonuria from the perspectives of patients in Türkiye
Background: The present study aimed to determine the problems, unmet needs and expectations of phenylketonuria (PKU) patients in Türkiye regarding follow-up and treatment in order to provide data for future planning and implementations on PKU. Methods: The study included patients diagnosed with PKU and/or their parents. They were informed about the study via phone calls and their verbal consents were obtained. Questions in the data collection forms, which were established separately for pediatric, adolescent, and adult age groups, were applied during the interviews and the answers were recorded. Results: Among 182 classical PKU patients, 66 (36.3%) were in the pediatric group (0–12 years old), 44 (24.2%) were in the adolescent group (13–19 years old), and 72 (39.5%) were in the adult group (≥ 20 years old). In all patient groups, phenylalanine-restricted diet and medical nutrition products were the main options for treatment. The median of the last measured blood phenylalanine concentration (patient-reported) was 290 µmol/L, 425 µmol/L, and 750 µmol/L in the pediatric, adolescent, and adult groups, respectively. The frequency of blood testing for serum phenylalanine level according to the age groups was appropriate in nearly half of the patients. While the majority of the patients have been visiting the metabolism center they have been diagnosed with PKU for control, considerable proportion of the patients would like to change the center or the doctor they visit for control if they could. It was determined that nearly half of the patients had trouble in accessing the metabolism center. Treatment options’ being limited and expensive were the major problems. The main requests of the patients and patient relatives included easier access to the metabolism centers and more options for treatment and diet. Conclusions: Access to the services should be easier to improve the patients’ follow-up and treatment. There is need for low-cost, easily applicable, and accessible nutrition products and effective novel pharmacological agents. Focusing on these issues in health policies by providing pedagogic/psychological support, establishing support programs also comprising the families, and increasing the awareness activities were the key outcomes.
- 1 January 2024
- Published by Bayt Publications in The Turkish Journal of Geriatrics
- Vol. 27 (3) , 280-291
POTENTIALLY INAPPROPRIATE ANTIDEPRESSANT USE IN OLDER PEOPLE COMPARED WITH THE ADULT POPULATION IN TÜRKIYE
Introduction: The prevalence of polypharmacy in older people contributes to potentially inappropriate prescribing, which is evaluated using various criteria. Depressive disorders are serious issues for older adults. In this study, the prescribing rates of potentially inappropriate antidepressants in older age groups in Türkiye were compared with younger age groups. Materials and Method: All electronic prescriptions including those for antidepressants, in Türkiye, issued by family physicians in 2019 were obtained using the Prescription Information System. Data were analyzed using the Beers Criteria 2019 update. Results: Of all prescriptions, 0.63% written for older people (65 years and over) were “Potentially Inappropriate Medication” classified antidepressant medications. A significantly lower percentage of “Potentially Inappropriate Medication” classified prescriptions, was observed for older people compared to the rate of total prescriptions (30.6% vs 32%). Paroxetine and amitriptyline had the highest prescription rates for older people. Older people received significantly more “Drugs to be Used With Caution” (35.6% vs. 32%). The top five most frequently prescribed “Drugs to be Used With Caution” for older people were escitalopram, sertraline, duloxetine, citalopram, and mirtazapine. Conclusions: There was a lower rate of prescribing of “Potentially Inappropriate Medication” for older people (65 years and over) than for younger (between 18-65 years) people. This suggests that family physicians are aware of the potential inappropriateness of specific antidepressants and prescribe them less frequently. Additionally, increased prescribing of “Drugs to be Used With Caution” in elderly can be associated with the limited availability of completely safe drugs in this population. Keywords: Antidepressive Agents; Geriatrics; Potentially Inappropriate Medication List; Prescriptions.
- 1 January 2024
- Published by Bayt Publications in The Turkish Journal of Geriatrics
- Vol. 27 (3) , 280-291
POTENTIALLY INAPPROPRIATE ANTIDEPRESSANT USE IN OLDER PEOPLE COMPARED WITH THE ADULT POPULATION IN TÜRKIYE
Introduction: The prevalence of polypharmacy in older people contributes to potentially inappropriate prescribing, which is evaluated using various criteria. Depressive disorders are serious issues for older adults. In this study, the prescribing rates of potentially inappropriate antidepressants in older age groups in Türkiye were compared with younger age groups. Materials and Method: All electronic prescriptions including those for antidepressants, in Türkiye, issued by family physicians in 2019 were obtained using the Prescription Information System. Data were analyzed using the Beers Criteria 2019 update. Results: Of all prescriptions, 0.63% written for older people (65 years and over) were “Potentially Inappropriate Medication” classified antidepressant medications. A significantly lower percentage of “Potentially Inappropriate Medication” classified prescriptions, was observed for older people compared to the rate of total prescriptions (30.6% vs 32%). Paroxetine and amitriptyline had the highest prescription rates for older people. Older people received significantly more “Drugs to be Used With Caution” (35.6% vs. 32%). The top five most frequently prescribed “Drugs to be Used With Caution” for older people were escitalopram, sertraline, duloxetine, citalopram, and mirtazapine. Conclusions: There was a lower rate of prescribing of “Potentially Inappropriate Medication” for older people (65 years and over) than for younger (between 18-65 years) people. This suggests that family physicians are aware of the potential inappropriateness of specific antidepressants and prescribe them less frequently. Additionally, increased prescribing of “Drugs to be Used With Caution” in elderly can be associated with the limited availability of completely safe drugs in this population. Keywords: Antidepressive Agents; Geriatrics; Potentially Inappropriate Medication List; Prescriptions.
- 19 January 2021
- Published by Springer Nature in Indian Journal of Orthopaedics
- Vol. 55 (4) , 886-891
Steroid Injection and Biomarker Levels in the Treatment of Unicameral Bone Cysts: Can we Estimate the Result?
Background Steroid injection is a common method in the treatment of unicameral bone cysts (UBC). In this study, the relationship between the clinical results and inflammatory molecules’ levels in the cyst fluid was evaluated after three repeated steroid injections in UBC subjects. Methods Twenty-one patients diagnosed with UBC were treated with methylprednisolone acetate (MPA) injections. Patients were given three injections, each containing MPA, 6–8 weeks apart. Plain radiographs were obtained and cyst healing was evaluated according to modified Neer classification. Cyst fluid samples were taken. Samples were taken at first and last operations and were studied using the ELISA method to examine IL-1β, PGE2, MMP-1, and VEGF-A levels. Results There were 17 and 4 cases localized to the humerus and femur, respectively. The mean follow-up period was 36.9 months. Complete recovery was achieved in 13 patients (61.9%) receiving MPA. Four patients (19%) recovered with residual lesions. One patient (4.7%) did not respond to steroid injections at all. In three patients (14.2%) the cyst recurred. Results were satisfactory in 17 patients (80.9%) and totally unsuccessful in 4 patients (19%). IL-1β, PGE2, and MMP-1 levels in cyst fluid were not affected by injection (p > 0.05), but VEGF-A levels decreased significantly with cyst healing (p = 0.01). Conclusion Steroid injection is a good choice in the treatment of UBC because of its less aggressive and relatively good outcome. It may be considered to evaluate the response to treatment by performing biomarker monitoring especially VEGF-A in repeated injections. Level of Evidence Level II study.
- 19 January 2021
- Published by Springer Nature in Indian Journal of Orthopaedics
- Vol. 55 (4) , 886-891
Steroid Injection and Biomarker Levels in the Treatment of Unicameral Bone Cysts: Can we Estimate the Result?
Background Steroid injection is a common method in the treatment of unicameral bone cysts (UBC). In this study, the relationship between the clinical results and inflammatory molecules’ levels in the cyst fluid was evaluated after three repeated steroid injections in UBC subjects. Methods Twenty-one patients diagnosed with UBC were treated with methylprednisolone acetate (MPA) injections. Patients were given three injections, each containing MPA, 6–8 weeks apart. Plain radiographs were obtained and cyst healing was evaluated according to modified Neer classification. Cyst fluid samples were taken. Samples were taken at first and last operations and were studied using the ELISA method to examine IL-1β, PGE2, MMP-1, and VEGF-A levels. Results There were 17 and 4 cases localized to the humerus and femur, respectively. The mean follow-up period was 36.9 months. Complete recovery was achieved in 13 patients (61.9%) receiving MPA. Four patients (19%) recovered with residual lesions. One patient (4.7%) did not respond to steroid injections at all. In three patients (14.2%) the cyst recurred. Results were satisfactory in 17 patients (80.9%) and totally unsuccessful in 4 patients (19%). IL-1β, PGE2, and MMP-1 levels in cyst fluid were not affected by injection (p > 0.05), but VEGF-A levels decreased significantly with cyst healing (p = 0.01). Conclusion Steroid injection is a good choice in the treatment of UBC because of its less aggressive and relatively good outcome. It may be considered to evaluate the response to treatment by performing biomarker monitoring especially VEGF-A in repeated injections. Level of Evidence Level II study.
- Open Access
- 1 January 2021
- Published by Turkiye Klinikleri in Turkiye Klinikleri Journal of Medical Sciences
- Vol. 41 (1) , 51-62
The Awareness of Drug Classifications and Concept of High Risk Drug by Healthcare Workers and Their Place in Professional Practice
Amaç: İlaç sınıflandırmaları, sağlık çalışanlarına lisans eğitimi sırasında, ağırlıklı olarak tedavide kullanıldıkları sistemlere göre öğretilmektedir. Dünya Sağlık Örgütü tarafından tanımlanan Anatomik Terapötik Kimyasal [Anatomical Therapeutic Chemical (ATC)] sınıflandırma sistemi başta olmak üzere bilinen ve kullanılan birçok sınıflama bulunmaktadır. Burada sunduğumuz anket çalışmasının amacı, sağlık çalışanlarının ilaç sınıflandırmaları ve spesifik olarak 'yüksek riskli ilaçlar' ile ilgili bilgi düzeyini ve rutin kullanımdaki tutumlarını belirlemektir. Gereç ve Yöntemler: Çalışmamız, 256 sağlık çalışanına çevirim içi olarak çeşitli sosyal medya ve direkt mesajlaşma uygulamaları vasıtasıyla ulaşılarak, 19 soruluk bir anket ile gerçekleştirilmiştir. Sağlık çalışanlarının sınıflandırmalarla ilgili bilgi düzeyi ve tutumu ve 'yüksek riskli ilaç' sınıflandırması ile ilgili spesifik bilgi düzeyi verileri toplanmıştır. Bulgular: Çalışmaya 130 (%50,8) tıp doktoru, 71 (%27,7) eczacı ve 55 (%21,5) hemşire katılmıştır. Katılımcıların 129 (%50,4)'u ATC ilaç sınıflandırmasını bilmediğini ve 182 (%71,4)'si rutinde kullanmadığını ifade etmiştir. Yüksek riskli ilaçlar ile ilgili spesifik ilaç risk sınıflandırması sorularına doğru yanıt veren katılımcı sayıları 146 (%59,3) ve 184 (%74,5) olmuştur. Sonuç: İlaçları sınıflandırmanın temel amacı, ilacın en yüksek fayda ile en güvenli şekilde kullanılmasını sağlamakla birlikte sağlık çalışanlarının da mesleki pratiklerini kolaylaştırmaktır. Akılcı ilaç kullanımı ilkeleri bağlamında ilaç reçeteleme, hazırlama ve uygulamadan sorumlu sağlık profesyonellerinin farkındalık ve bilgi düzeyinin mezuniyet sonrası eğitimlerle artırılmasında fayda olacağı düşünülmüştür.
- 1 January 2021
- Published by Turkiye Klinikleri in Turkiye Klinikleri Journal of Medical Sciences
- Vol. 41 (1) , 51-62
Open AccessThe Awareness of Drug Classifications and Concept of High Risk Drug by Healthcare Workers and Their Place in Professional Practice
Amaç: İlaç sınıflandırmaları, sağlık çalışanlarına lisans eğitimi sırasında, ağırlıklı olarak tedavide kullanıldıkları sistemlere göre öğretilmektedir. Dünya Sağlık Örgütü tarafından tanımlanan Anatomik Terapötik Kimyasal [Anatomical Therapeutic Chemical (ATC)] sınıflandırma sistemi başta olmak üzere bilinen ve kullanılan birçok sınıflama bulunmaktadır. Burada sunduğumuz anket çalışmasının amacı, sağlık çalışanlarının ilaç sınıflandırmaları ve spesifik olarak 'yüksek riskli ilaçlar' ile ilgili bilgi düzeyini ve rutin kullanımdaki tutumlarını belirlemektir. Gereç ve Yöntemler: Çalışmamız, 256 sağlık çalışanına çevirim içi olarak çeşitli sosyal medya ve direkt mesajlaşma uygulamaları vasıtasıyla ulaşılarak, 19 soruluk bir anket ile gerçekleştirilmiştir. Sağlık çalışanlarının sınıflandırmalarla ilgili bilgi düzeyi ve tutumu ve 'yüksek riskli ilaç' sınıflandırması ile ilgili spesifik bilgi düzeyi verileri toplanmıştır. Bulgular: Çalışmaya 130 (%50,8) tıp doktoru, 71 (%27,7) eczacı ve 55 (%21,5) hemşire katılmıştır. Katılımcıların 129 (%50,4)'u ATC ilaç sınıflandırmasını bilmediğini ve 182 (%71,4)'si rutinde kullanmadığını ifade etmiştir. Yüksek riskli ilaçlar ile ilgili spesifik ilaç risk sınıflandırması sorularına doğru yanıt veren katılımcı sayıları 146 (%59,3) ve 184 (%74,5) olmuştur. Sonuç: İlaçları sınıflandırmanın temel amacı, ilacın en yüksek fayda ile en güvenli şekilde kullanılmasını sağlamakla birlikte sağlık çalışanlarının da mesleki pratiklerini kolaylaştırmaktır. Akılcı ilaç kullanımı ilkeleri bağlamında ilaç reçeteleme, hazırlama ve uygulamadan sorumlu sağlık profesyonellerinin farkındalık ve bilgi düzeyinin mezuniyet sonrası eğitimlerle artırılmasında fayda olacağı düşünülmüştür.
- 19 February 2019
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 86 (6) , 565-567
Fatal Agranulocytosis and Fournier’s Gangrene due to the Use of Metamizole: Correspondence
- 19 February 2019
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 86 (6) , 565-567
Fatal Agranulocytosis and Fournier’s Gangrene due to the Use of Metamizole: Correspondence
- 1 May 2017
- Published by Edizioni Minerva Medica in Journal of Neurosurgical Sciences
- Vol. 61 (4) , 380-387
Dipyrone attenuates cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits
Article: Dipyrone attenuates cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits - Journal of Neurosurgical Sciences 2017 August;61(4):380-7 - Minerva Medica - Journals
- 1 May 2017
- Published by Edizioni Minerva Medica in Journal of Neurosurgical Sciences
- Vol. 61 (4) , 380-387
Dipyrone attenuates cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits
Article: Dipyrone attenuates cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits - Journal of Neurosurgical Sciences 2017 August;61(4):380-7 - Minerva Medica - Journals
- 12 September 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 25 (1) , 229-236
Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients
Due to more comorbidities, polypharmacy is common in elderly patients and drug interactions are inevitable. It is also challenging to treat an elderly patient with a diagnosis of cancer. Prevalence and clinical impacts of drug interactions and using potentially inappropriate medications (PIMs) have been studied in geriatric patients. However, these are not well defined in oncology practice. The purpose of this study is to define the prevalence of PIMs and severe drug interactions (SDIs) in elderly cancer patients and investigate the factors associated with them. Patients more than 65 years of age in both inpatient and outpatient clinics were evaluated. Patient, disease characteristics, and medications used were collected by self reports and medical records. Drug interactions were checked with Lexicomp® and PIM was defined with 2012 update of Beers criteria. Severe drug interactions are defined with category D or X DIs. Logistic regression was used to compute odds ratios (ORs) and 95 % confidence intervals (CIs) for the association between SDIs, PIMs, and clinical parameters. Four hundered and forty-five elderly patients (286 outpatient, 159 inpatient), with a median age of 70 (65–89) were evaluated. SDIs were present in 156 (35.1 %) of patients, 81 (28.3 %), and 75 (47.2 %) for outpatient and inpatients, respectively (p < 0.001). PIMs were present in 117 (26.6 %) of the patients, 40 (14.2 %), and 77(48.4 %) for outpatient and inpatients, respectively (p < 0.001). In multivariate analysis; polypharmacy (≥5 drugs), inpatient status and diagnosis of lung cancer were associated with severe DIs. Polypharmacy, inpatient status, and bad performance score (ECOG 3–4) were associated with PIMs. Nearly one third of the elderly cancer patients are exposed to severe drug interactions and PIMs. Clinicians dealing with elderly cancer patients should be more cautious when prescribing/ planning drugs to this group of patients. More strategies should be developed in this group of patients to minimize the medications prescribed and prevent severe DIs.
- 12 September 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 25 (1) , 229-236
Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients
Due to more comorbidities, polypharmacy is common in elderly patients and drug interactions are inevitable. It is also challenging to treat an elderly patient with a diagnosis of cancer. Prevalence and clinical impacts of drug interactions and using potentially inappropriate medications (PIMs) have been studied in geriatric patients. However, these are not well defined in oncology practice. The purpose of this study is to define the prevalence of PIMs and severe drug interactions (SDIs) in elderly cancer patients and investigate the factors associated with them. Patients more than 65 years of age in both inpatient and outpatient clinics were evaluated. Patient, disease characteristics, and medications used were collected by self reports and medical records. Drug interactions were checked with Lexicomp® and PIM was defined with 2012 update of Beers criteria. Severe drug interactions are defined with category D or X DIs. Logistic regression was used to compute odds ratios (ORs) and 95 % confidence intervals (CIs) for the association between SDIs, PIMs, and clinical parameters. Four hundered and forty-five elderly patients (286 outpatient, 159 inpatient), with a median age of 70 (65–89) were evaluated. SDIs were present in 156 (35.1 %) of patients, 81 (28.3 %), and 75 (47.2 %) for outpatient and inpatients, respectively (p < 0.001). PIMs were present in 117 (26.6 %) of the patients, 40 (14.2 %), and 77(48.4 %) for outpatient and inpatients, respectively (p < 0.001). In multivariate analysis; polypharmacy (≥5 drugs), inpatient status and diagnosis of lung cancer were associated with severe DIs. Polypharmacy, inpatient status, and bad performance score (ECOG 3–4) were associated with PIMs. Nearly one third of the elderly cancer patients are exposed to severe drug interactions and PIMs. Clinicians dealing with elderly cancer patients should be more cautious when prescribing/ planning drugs to this group of patients. More strategies should be developed in this group of patients to minimize the medications prescribed and prevent severe DIs.